Venetoclax-based combination therapy in R/R DLBCL patients with failure of CAR-T therapy

Zhu, Ying; Ai, Sicheng; Cong, Mengya; Jin, Mao; Ma, Xiao; Huang, Haiwen

doi:10.1007/s00277-023-05088-7

Cited by 3 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, Zhu Y, et al reported a study focusing on the outcomes of venetoclax for patients with DLBCL post-CAR Tcell therapy, involving a cohort of 10 patients. The achieved ORR was 80%, and the CR was 30% (92). Further case studies have also cited the use of agents like BTKi, histone deacetylase inhibitors, and ibrutinib (93,94).…”

Section: Other Therapiesmentioning

confidence: 99%

Treatment strategies for relapse after CAR T-cell therapy in B cell lymphoma

Negishi,

Girsch,

Siegler

et al. 2024

Front. Pediatr.

View full text Add to dashboard Cite

Clinical trials of anti-CD19 chimeric antigen receptor T (CART19) cell therapy have shown high overall response rates in patients with relapsed/refractory B-cell malignancies. CART19 cell therapy has been approved by the US Food and Drug Administration for patients who relapsed less than 12 months after initial therapy or who are refractory to first-line therapy. However, durable remission of CART19 cell therapy is still lacking, and 30%–60% of patients will eventually relapse after CART19 infusion. In general, the prognosis of patients who relapse after CART19 cell therapy is poor, and various strategies to treat this patient population have been investigated extensively. CART19 failures can be broadly categorized by the emergence of either CD19-positive or CD19-negative lymphoma cells. If CD19 expression is preserved on the lymphoma cells, a second infusion of CART19 cells or reactivation of previously infused CART19 cells with immune checkpoint inhibitors can be considered. When patients develop CD19-negative relapse, targeting different antigens (e.g., CD20 or CD22) with CAR T cells, investigational chemotherapies, or hematopoietic stem cell transplantation are potential treatment options. However, salvage therapies for relapsed large B-cell lymphoma after CART19 cell therapy have not been fully explored and are conducted based on clinicians' case-by-case decisions. In this review, we will focus on salvage therapies reported to date and discuss the management of relapsed/refractory large B-cell lymphomas after CART19 cell therapy.

show abstract

Section: Other Therapiesmentioning

confidence: 99%

Treatment strategies for relapse after CAR T-cell therapy in B cell lymphoma

Negishi,

Girsch,

Siegler

et al. 2024

Front. Pediatr.

View full text Add to dashboard Cite

show abstract

“…Recently, Zhu et al . reported that venetoclax-based combination therapy resulted in an ORR of 80%, with 30% achieved CR in patients post CAR-T therapy [ 154 ]. Ongoing clinical trials are evaluating venetoclax in combination with other agents, including rituximab plus ibrutinib (NCT03136497), obinutuzumab plus lenalidomide (NCT02992522), and R-ICE chemotherapy (NCT03064867) in R/R DLBCLs.…”

Section: Introductionmentioning

confidence: 99%

The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma

Zhang

Xu-Monette

et al. 2023

Exp Hematol Oncol

View full text Add to dashboard Cite

Diffuse large B-cell lymphoma (DLBCL) can be cured with standard front-line immunochemotherapy, whereas nearly 30–40% of patients experience refractory or relapse. For several decades, the standard treatment strategy for fit relapsed/refractory (R/R) DLBCL patients has been high-dose chemotherapy followed by autologous hematopoietic stem cell transplant (auto-SCT). However, the patients who failed in salvage treatment or those ineligible for subsequent auto-SCT have dismal outcomes. Several immune-based therapies have been developed, including monoclonal antibodies, antibody–drug conjugates, bispecific T-cell engaging antibodies, chimeric antigen receptor T-cells, immune checkpoint inhibitors, and novel small molecules. Meanwhile, allogeneic SCT and radiotherapy are still necessary for disease control for fit patients with certain conditions. In this review, to expand clinical treatment options, we summarize the recent progress of immune-related therapies and prospect the future indirections in patients with R/R DLBCL.

show abstract

Advances in molecular targeted drugs in combination with CAR-T cell therapy for hematologic malignancies

Huang,

Qin,

et al. 2024

Drug Resistance Updates

View full text Add to dashboard Cite

Venetoclax-based combination therapy in R/R DLBCL patients with failure of CAR-T therapy

Cited by 3 publications

References 8 publications

Treatment strategies for relapse after CAR T-cell therapy in B cell lymphoma

Treatment strategies for relapse after CAR T-cell therapy in B cell lymphoma

The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma

Advances in molecular targeted drugs in combination with CAR-T cell therapy for hematologic malignancies

Contact Info

Product

Resources

About